Table 1 Baseline clinical characteristics and Cyr61 concentration of RA patients in the training cohort
From: Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis
Variables | Inactive RA (n = 104) | Active RA (n = 73) | P value |
|---|---|---|---|
Age (years) | 51.97 ± 13.27 | 54.27 ± 15.96 | 0.158 |
BMI (kg/m2) | 20.68 ± 5.19 | 22.19 ± 6.74 | 0.486 |
Gender (female, %) | 81 (77.88%) | 62 (84.93%) | 0.332 |
Cyr61 concentration (pg/ml) | 226.85 (152.50–339.96) | 189.92 (129.58–254.47) | 0.004 |
Disease duration (months) | 60 (32–135) | 64 (27–132) | 0.68 |
RF-positive (n, %) | 81 (77.88%) | 57 (78.08%) | 1.000 |
ACPA-positive (n, %) | 88 (84.62%) | 60 (82.19%) | 0.832 |
Disease activity | |||
ESR (mm/h) | 10 (5–18) | 27 (17–47) | < 0.001 |
CRP (mg/l) | 3.26 (1.90–5.55) | 8.89 (4.18–18.70) | < 0.001 |
TJC (0–28) | 0 (0–1) | 6 (3–10) | < 0.001 |
SJT (0–28) | 0 (0–0) | 2 (1–4) | < 0.001 |
PGA (0–100) | 10 (0–15) | 50 (30–60) | < 0.001 |
EGA (0–100) | 5 (0–10) | 50 (30–60) | < 0.001 |
DAS28-ESR | 1.92 (1.41–2.48) | 4.64 (3.81–5.62) | < 0.001 |
DAS28-CRP | 1.76 (1.50–2.26) | 4.19 (3.20–5.21) | < 0.001 |
SDAI | 2.15 (0.63–5.04) | 18.30 (11.73–29.65) | < 0.001 |
CDAI | 1.50 (0.10–4.38) | 17.00 (11.00–27.00) | < 0.001 |
Medication in use (n, %) | |||
Methotrexate | 82 (78.85%) | 59 (80.82%) | 0.850 |
Glucocorticoids | 15 (14.42%) | 17 (23.28%) | 0.165 |
Leflunomide | 7 (6.73%) | 9 (12.33%) | 0.287 |
Hydroxychloroquine | 41 (39.42%) | 25 (34.25%) | 0.529 |
Sulfasalazine | 6 (5.77%) | 6 (8.22%) | 0.553 |
TNF inhibitors | 2 (1.92%) | 4 (5.48%) | 0.232 |